Clinical Trial Update: A Study to Investigate the Safety, Tolerability and Pharmacokinetics of Single and Repeat Doses of RV1729 for up to 28 Days [Phase 1]

View source ↗

Summary

A Phase 1 study evaluating safety, tolerability, and pharmacokinetics of single and repeat doses of RV1729 in individuals with asthma and in healthy volunteers;…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Asthma

Drugs mentioned

• RV1729

Snippet

Sponsor: Respivert Ltd | Conditions: Asthma, Healthy Volunteers | Phase 1 | Status: COMPLETED